Healios KKHLOSF 57 Pretax Margin % is -43,660.00% as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Healios KK ranks worse than 88.35% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Healios KK's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-21.83 Mil. Healios KK's Revenue for the
three
months ended in Mar. 2026 was $0.05 Mil. Therefore, Healios KK's pretax margin for the quarter that ended in Mar. 2026 was -43,660.00%.
The historical rank and industry rank for Healios KK's Pretax Margin % or its related term are showing as below:
HLOSF'
s Pretax Margin % Range Over the Past 10 Years
Min: -19918.52 Med: -5122.47 Max: -725.18
Current: -4068.92
HLOSF's Pretax Margin % is ranked worse than 88.35% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs HLOSF: -4068.92
Healios KK (OTCPK:HLOSF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Healios KK Pretax Margin % Related Terms
Healios KK Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Healios KK's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLOSF vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Healios KK's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Healios KK's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (HLOSF) has a Pretax Margin % of -43,660.00% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #834 out of 944 companies in the Biotechnology industry, placing it in the top 88.3%.
Is Healios KK's Pretax Margin % too high?
Healios KK's current Pretax Margin % is -43,660.00%. Based on the distribution chart, Healios KK ranks #834 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #834 out of 944 companies for Pretax Margin %. This places Healios KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Healios KK and its competitors. Healios KK's current Pretax Margin % is -43,660.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current Pretax Margin % is -43,660.00%. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Healios KK (HLOSF), the current Pretax Margin % is -43,660.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
Pretax Margin %: -43,660.00%
GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
